


644/1614

PATENT APPLICATION

Applicants : Tugrul T. KARARLI et al
Title : OPTHALMIC FORMULATION OF A SELECTIVE
CYCLOOXYGENASE-2 INHIBITORY DRUG
Serial No. : 09/904 098 Group: 1360
Confirmation No.: 1335
Filed : July 12, 2001 Examiner: Unknown
Atty. Docket
No.: Pharmacia Case 3351.2

RECEIVED
APR 15 2002
TECH CENTER 1637/2900


Assistant Commissioner for Patents
Washington, DC 20231



FIRST CLASS MAILING CERTIFICATE

Sir:

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.8 as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington DC 20231, on March 28, 2002.


Terryence F. Chapman

TFC/smd

FLYNN, THIEL, BOUTELL	Dale H. Thiel	Reg. No. 24 323
& TANIS, P.C.	David G. Boutell	Reg. No. 25 072
2026 Rambling Road	Ronald J. Tanis	Reg. No. 22 724
Kalamazoo, MI 49008-1699	Terryence F. Chapman	Reg. No. 32 549
Phone: (616) 381-1156	Mark L. Maki	Reg. No. 36 589
Fax: (616) 381-5465	David S. Goldenberg	Reg. No. 31 257
	Sidney B. Williams, Jr.	Reg. No. 24 949
	Liane L. Churney	Reg. No. 40 694
	Brian R. Tumm	Reg. No. 36 328
	Tricia R. Cobb	Reg. No. 44 621

Correspondence: Information Disclosure Statement
dated March 28, 2002
including enclosures listed thereon

190.0112



RECEIVED
APR 15 2002
TECH CENTER 1600/2900

PATENT APPLICATION

THE U.S. PATENT AND TRADEMARK OFFICE

March 28, 2002

Applicants: Tugrul T. KARARLI et al

For: OPHTHALMIC FORMULATION OF A SELECTIVE
CYCLOOXYGENASE-2 INHIBITORY DRUG

Serial No.: 09/904 098 Group: 1360

Confirmation No.: 1335

Filed: July 12, 2001 Examiner: Unknown

Atty. Docket No.: Pharmacia Case 3351.2

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Sir:

In compliance with the provisions of Rules 1.97(b)(3) and 1.98, enclosed herewith is Form PTO-1449. Due to the numerous references, they are being mailed to the Patent Office in three boxes under separate cover. These references are mentioned in Applicants' specification and are considered to be the most pertinent of the references discussed therein. Further comment at this point in time should not be necessary.

Further consideration is respectfully solicited.

Respectfully submitted,

TFC/smd


Terryence F. Chapman

FLYNN, THIEL, BOUTELL	Dale H. Thiel	Reg. No. 24 323
& TANIS, P.C.	David G. Boutell	Reg. No. 25 072
2026 Rambling Road	Ronald J. Tanis	Reg. No. 22 724
Kalamazoo, MI 49008-1699	Terryence F. Chapman	Reg. No. 32 549
Phone: (616) 381-1156	Mark L. Maki	Reg. No. 36 589
Fax: (616) 381-5465	David S. Goldenberg	Reg. No. 31 257
	Sidney B. Williams, Jr.	Reg. No. 24 949
	Liane L. Churney	Reg. No. 40 694
	Brian R. Tumm	Reg. No. 36 328
	Tricia R. Cobb	Reg. No. 44 621

Encl: Form PTO-1449 (13 pages)
Postal Card

136.0112

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION	Applicant: Tugrul T. KARARLI et al Ser.No. : 09/904 098 Filed : July 12, 2001 Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2 Group : 1360
---------------------------------------	--

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 3 863 633	2/1975	RYDE et al			
	AB 3 868 445	2/1975	RYDE et al			
	AC 4 281 654	8/1981	SHELL et al			
	AD 4 478 818	10/1984	SHELL et al			
	AE 4 559 343	12/1985	HAN et al			
	AF 4 826 689	5/1989	VIOLANTO et al			
	AG 4 829 083	5/1989	DOULAKAS			
	AH 4 829 088	5/1989	DOULAKAS			
	AI 4 861 760	8/1989	MAZUEL et al			
	AJ 4 913 903	4/1990	SUDMANN et al			
	AK 4 960 799	10/1990	NAGY			
	AL 5 001 153	3/1991	UENO et al			
	AM 5 110 493	5/1992	CHERNG-CHYI et al			
	AN 5 145 684	9/1992	LIVERSIDGE et al			
	AO 5 298 262	3/1994	NA et al			
	AP 5 302 401	4/1994	LIVERSIDGE et al			
	AQ 5 336 507	8/1994	NA et al			
	AR 5 340 564	8/1994	ILLIG et al			
	AS 5 344 991	9/1994	REITZ et al			
	AT 5 346 702	9/1994	NA et al			
	AU 5 352 459	10/1994	HOLLISTER et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 5 352 708	10/1994	WOODWARD et al			
	AB 5 354 560	10/1994	LOVRECICH			
	AC 5 380 738	1/1995	NORMAN et al			
	AD 5 384 124	1/1995	COURTEILLE et al			
	AE 5 393 790	2/1995	REITZ et al			
	AF 5 401 765	3/1995	LEE			
	AG 5 418 254	5/1995	HUANG et al			
	AH 5 420 343	5/1995	KOSZYK et al			
	AI 5 422 368	6/1995	STJERNSCHANTZ et al			
	AJ 5 429 824	7/1995	JUNE			
	AK 5 434 178	7/1995	TALLEY et al			
	AL 5 436 265	7/1995	BLACK et al			
	AM 5 443 505	8/1995	WONG et al			
	AN 5 466 823	11/1995	TALLEY et al			
	AO 5 474 995	12/1995	DUCHARME et al			
	AP 5 475 018	12/1995	LEE et al			
	AQ 5 486 534	1/1996	LEE et al			
	AR 5 503 723	4/1996	RUDDY et al			
	AS 5 510 118	4/1996	BOSCH et al			
	AT 5 510 368	4/1996	LAU et al			
	AU 5 510 383	4/1996	BISHOP et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360


U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 5 515 444	5/1996	BURDISO et al			
	AB 5 518 187	5/1996	BRUNO et al			
	AC 5 518 738	5/1996	EICKHOFF et al			
	AD 5 521 213	5/1996	PRASIT et al			
	AE 5 534 270	7/1996	DeCASTRO			
	AF 5 536 508	7/1996	CANAL et al			
	AG 5 536 752	7/1996	DUCHARME et al			
	AH 5 543 297	8/1996	CROMLISH et al			
	AI 5 547 975	8/1996	TALLEY et al			
	AJ 5 550 142	8/1996	DUCHARME et al			
	AK 5 552 160	9/1996	LIVERSIDGE et al			
	AL 5 552 422	9/1996	GAUTHIER et al			
	AM 5 560 931	10/1996	EICKHOFF et al			
	AN 5 560 932	10/1996	BAGCHI et al			
	AO 5 565 188	10/1996	WONG et al			
	AP 5 569 448	10/1996	WONG et al			
	AQ 5 571 536	11/1996	EICKHOFF et al			
	AR 5 573 783	11/1996	DESIENO et al			
	AS 5 580 579	12/1996	RUDDY et al			
	AT 5 585 108	12/1996	RUDDY et al			
	AU 5 585 504	12/1996	DESMOND et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
APR 15 2002
TECH CENTER 1600/2900

• INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 5 587 143	12/1996	WONG			
	AB 5 591 456	1/1997	FRANSON et al			
	AC 5 593 992	1/1997	ADAMS et al			
	AD 5 596 008	1/1997	LEE			
	AE 5 604 253	2/1997	LAU et al			
	AF 5 604 260	2/1997	GUAY et al			
	AG 5 607 978	3/1997	WOODWARD et al			
	AH 5 616 458	4/1997	LIPSKY et al			
	AI 5 616 601	4/1997	KHANNA et al			
	AJ 5 620 999	4/1997	WEIER et al			
	AK 5 622 938	4/1997	WONG			
	AL 5 632 984	5/1997	WONG et al			
	AM 5 633 272	5/1997	TALLEY et al			
	AN 5 639 780	6/1997	LAU et al			
	AO 5 643 933	7/1997	TALLEY et al			
	AP 5 658 897	8/1997	BURK			
	AQ 5 658 903	8/1997	ADAMS et al			
	AR 5 662 883	9/1997	BAGCHI et al			
	AS 5 665 331	9/1997	BAGCHI et al			
	AT 5 665 773	9/1997	KLIMKO et al			
	AU 5 668 161	9/1997	TALLEY et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 5 670 510	9/1997	HUANG et al			
	AB 5 677 318	10/1997	LAU			
	AC 5 681 842	10/1997	DELLARIA et al			
	AD 5 686 460	11/1997	NICOLAI et al			
	AE 5 686 470	11/1997	WEIER et al			
	AF 5 688 819	11/1997	WOODWARD et al			
	AG 5 696 143	12/1997	TALLEY et al			
	AH 5 710 140	1/1998	DUCHARME et al			
	AI 5 716 955	2/1998	ADAMS et al			
	AJ 5 718 919	2/1998	RUDDY et al			
	AK 5 723 485	3/1998	GUNGOR et al			
	AL 5 739 166	4/1998	REITZ et al			
	AM 5 741 798	4/1998	LAZER et al			
	AN 5 747 001	5/1998	WIEDMANN et al			
	AO 5 756 499	5/1998	ADAMS et al			
	AP 5 756 529	5/1998	ISAKSON et al			
	AQ 5 760 068	6/1998	TALLEY et al			
	AR 5 767 153	6/1998	BOWMAN et al			
	AS 5 776 967	7/1998	KREFT et al			
	AT 5 783 597	7/1998	BEERS et al			
	AU 5 789 413	8/1998	BLACK et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION	Applicant:	Tugrul T. KARARLI et al	
	Ser.No. :	09/904 098	Filed : July 12, 2001
	Conf. No.:	1335	Atty.Ref.: Pharmacia Case 3351.2
	Group :	1360	

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA	5 807 873	9/1998	NICOLAI et al		
	AB	5 814 655	9/1998	PATEL et al		
	AC	5 817 700	10/1998	DUBE et al		
	AD	5 830 911	11/1998	FAILLI et al		
	AE	5 834 498	11/1998	BURK		
	AF	5 849 943	12/1998	ATKINSON et al		
	AG	5 859 036	1/1999	SARTORI et al		
	AH	5 861 419	1/1999	DUBE et al		
	AI	5 866 596	2/1999	SARTORI et al		
	AJ	5 869 079	2/1999	WONG et al		
	AK	5 869 524	2/1999	FAILLI		
	AL	5 869 660	2/1999	ADAMS et al		
	AM	5 883 267	3/1999	ROSSEN et al		
	AN	5 889 052	3/1999	KLIMKO et al		
	AO	5 892 053	4/1999	ZHI et al		
	AP	5 922 742	7/1999	BLACK et al		
	AQ	5 929 076	7/1999	ADAMS et al		
	AR	5 932 598	8/1999	TALLEY et al		
	AS	5 935 990	8/1999	KHANNA et al		
	AT	5 945 539	8/1999	HARUTA et al		
	AU	5 948 401	9/1999	DONABEDIAN et al		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
 Ser.No. : 09/904 098 Filed : July 12, 2001
 Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
 Group : 1360

RECEIVED
 APR 15 2002
 TECH CENTER 1600/2900


U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 5 952 378	9/1999	STJERNSCHANTZ et al			
	AB 5 958 978	9/1999	YAMAZAKI et al			
	AC 5 968 958	10/1999	GUAY et al			
	AD 5 972 950	10/1999	NICOLAI et al			
	AE 5 972 991	10/1999	BURK			
	AF 5 973 191	10/1999	MARNETT et al			
	AG 5 981 576	11/1999	BELLEY et al			
	AH 5 994 381	11/1999	HARUTA et al			
	AI 6 002 014	12/1999	HARUTA et al			
	AJ 6 004 960	12/1999	LI et al			
	AK 6 005 000	12/1999	HOPPER et al			
	AL 6 020 343	2/2000	BELLEY et al			
	AM 6 020 347	2/2000	DeLASZLO et al			
	AN 6 034 256	3/2000	CARTER et al			
	AO 6 037 364	3/2000	BURK			
	AP 6 040 319	3/2000	CORLEY et al			
	AQ 6 040 450	3/2000	DAVIES et al			
	AR 6 046 208	4/2000	ADAMS et al			
	AS 6 046 217	4/2000	FRIESEN et al			
	AT 6 057 319	5/2000	BLACK et al			
	AU 6 063 804	5/2000	DeNANTEUIL et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date
	AA 6 063 807	5/2000	CHABRIER de LASSAUNIERE et al			
	AB 6 071 954	6/2000	LeBLANC et al			
	AC 6 075 066	6/2000	MATSUDA et al			
	AD 6 077 868	6/2000	COOK et al			
	AE 6 077 869	6/2000	SUI et al			
	AF 6 083 969	7/2000	FERRO et al			
	AG 6 096 753	8/2000	SPOHR et al			
	AH 6 124 344	9/2000	BURK			
	AI 6 133 292	10/2000	WANG et al			
	AJ 6 160 129	12/2000	BURK			
	AK 6 204 287	3/2001	BURK			
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes No
	AA EP 0 424 043	5/1993	EUROPE			
	AB EP 0 799 823	10/1997	EUROPE			
	AC EP 0 846 689	6/1998	EUROPE			
	AD EP 0 863 134	9/1998	EUROPE			
	AE EP 0 985 666	3/2000	EUROPE			
	AF WO 92/00707	1/1992	WIPO			
	AG WO 93/25190	12/1993	WIPO			
	AH WO 94/15932	7/1994	WIPO			
✓	AI WO 95/03784	2/1995	WIPO			
✓	AJ WO 95/18604	7/1995	WIPO			
	AK WO 95/31968	11/1995	WIPO			
✓	AL WO 96/19469	6/1996	WIPO			
✓	AM WO 96/24336	8/1996	WIPO			
✓	AN WO 96/26921	9/1996	WIPO			
✓	AO WO 96/31509	10/1996	WIPO			
✓	AP WO 96/36623	11/1996	WIPO			
✓	AQ WO 96/38418	12/1996	WIPO			
	AR WO 97/03953	2/1997	WIPO			
	AS WO 97/10840	3/1997	WIPO			
	AT WO 97/13755	4/1997	WIPO			
	AU WO 97/13767	4/1997	WIPO			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No.: 09/904 098 Filed: July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group: 1360

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes No	
✓	AA	WO 97/14047	4/1997	WIPO				
✓	AB	WO 97/25048	7/1997	WIPO				
✓	AC	WO 97/30030	8/1997	WIPO				
✓	AD	WO 97/34882	9/1997	WIPO				
✓	AE	WO 97/46524	11/1997	WIPO				
✓	AF	WO 98/04527	2/1998	WIPO				
✓	AG	WO 98/06708	2/1998	WIPO				
✓	AH	WO 98/07425	2/1998	WIPO				
✓	AI	WO 98/17292	4/1998	WIPO				
✓	AJ	WO 98/21195	5/1998	WIPO				
✓	AK	WO 98/22457	5/1998	WIPO				
✓	AL	WO 98/32732	7/1998	WIPO				
✓	AM	WO 98/35666	8/1998	WIPO				
✓	AN	WO 98/41516	9/1998	WIPO				
✓	AO	WO 98/43966	10/1998	WIPO				
✓	AP	WO 98/45294	10/1998	WIPO				
✓	AQ	WO 98/47871	10/1998	WIPO				
✓	AR	WO 99/01130	1/1999	WIPO				
✓	AS	WO 99/01131	1/1999	WIPO				
✓	AT	WO 99/01452	1/1999	WIPO				
✓	AU	WO 99/01455	1/1999	WIPO				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation	
							Yes	No
✓	AA	WO 99/10331	3/1999	WIPO				
✓	AB	WO 99/10332 ✓	3/1999	WIPO				
✓	AC	WO 99/11605 ✓	3/1999	WIPO				
✓	AD	WO 99/12930 ✓	3/1999	WIPO				
✓	AE	WO 99/14195	3/1999	WIPO				
✓	AF	WO 99/14205	3/1999	WIPO				
✓	AG	WO 99/15505	4/1999	WIPO				
✓	AH	WO 99/23087 ✓	5/1999	WIPO				
✓	AI	WO 99/24404	5/1999	WIPO				
✓	AJ	WO 99/25695	5/1999	WIPO				
✓	AK	WO 99/35130	7/1999	WIPO				
	AL	WO 99/61016	12/1999	WIPO				
✓	AM	WO 99/61436	12/1999	WIPO				
✓	AN	WO 99/62884	12/1999	WIPO				
✓	AO	WO 99/64415	12/1999	WIPO				
✓	AP	WO 99/65469	12/1999	WIPO				
✓	AQ	WO 00/01380	1/2000	WIPO				
✓	AR	WO 00/08024	2/2000	WIPO				
✓	AS	WO 00/10993	3/2000	WIPO				
✓	AT	WO 00/13684	3/2000	WIPO				
✓	AU	WO 00/18374	4/2000	WIPO				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
1360

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation	
							Yes	No
✓	AA	WO 00/18749	4/2000	WIPO				
✓	AB	WO 00/18753	4/2000	WIPO				
✓	AC	WO 00/23426	4/2000	WIPO				
✓	AD	WO 00/24719	5/2000	WIPO				
✓	AE	WO 00/26216	5/2000	WIPO				
✓	AF	WO 00/27369	5/2000	WIPO				
✓	AG	WO 00/30615	6/2000	WIPO				
✓	AH	WO 00/31072	6/2000	WIPO				
✓	AI	WO 00/32189	6/2000	WIPO				
✓	AJ	WO 00/40087	7/2000	WIPO				
✓	AK	WO 00/56348	9/2000	WIPO				
	AL							
	AM							
	AN							
	AO							
	AP							
	AQ							
	AR							
	AS							
	AT							
	AU							

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE
CITATION

Applicant: Tugrul T. KARARLI et al
Ser.No. : 09/904 098 Filed : July 12, 2001
Conf. No.: 1335 Atty.Ref.: Pharmacia Case 3351.2
Group : 1360

OTHER DOCUMENTS (Including Author, Title, Date, Pages, Etc.)

AA	"Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers", by T. Loftsson, PHARMAZIE, 53 (1998), pp. 733-740
AB	"Cyclooxygenase-2 Inhibitors: A New Approach to the Therapy of Ocular Inflammation", by Jaime L. Masferrer, PhD et al, SURVEY OF OPHTHALMOLOGY, Vol. 41, Supplement 2, February 1997, pp. S35-S40
AC	"Latanoprost Accelerates Disruption of the Blood-Aqueous Barrier and the Incidence of Angiographic Cystoid Macular Edema in Early Postoperative Pseudophakias", by Kensaku Miyake, M.D., et al, ARCH. OPHTHALMOL., Volume 117, January 1999, pp. 34-40
AD	Physicians' Desk Reference, 54 th Edition, 2000, pp. 491-492
AE	"Pharmaceutical Applications of Cyclodextrins. 2. <i>In Vivo</i> Drug Delivery", by Roger A. Rajewski et al, JOURNAL OF PHARMACEUTICAL SCIENCES, Volume 85, No. 11, November 11, 1996, pp. 1142, 1155-1159
AF	"Some studies into the properties of indomethacin suspensions intended for ophthalmic use", by Nenad Vulovic et al, INTERNATIONAL JOURNAL OF PHARMACEUTICS, 55 (1989), pp. 123-128
AG	"Comparative Comfort of Flurbiprofen Solution and Indomethacin Suspension Eyedrops", by P.S. Weisweiler et al, JOURNAL OF CLINICAL RESEARCH AND DRUG DEVELOPMENT, 2 (1988), pp. 233-239
AH	
AI	
AJ	
AK	
AL	
AM	
AN	
AO	
AP	
AQ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.